Document is current
Any future updates will be listed below
-
Authors
LaMarca, Elizabeth A.
Saito, Atsushi
Plaza-Jennings, Amara
Espeso-Gil, Sergio
Hellmich, Allyse
Fernando, Michael B. https://orcid.org/0000-0002-4620-8048
Javidfar, Behnam
Liao, Will https://orcid.org/0000-0001-7574-4694
Estill, Molly
Townsley, Kayla
Florio, Anna
Ethridge, James E.
Do, Catherine
Tycko, Benjamin
Shen, Li https://orcid.org/0000-0002-5190-2851
Kamiya, Atsushi https://orcid.org/0000-0002-4274-5567
Tsankova, Nadejda M.
Brennand, Kristen J.
Akbarian, Schahram https://orcid.org/0000-0001-7700-0891
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (1U01DA048279)
U.S. Department of Health & Human Services | NIH | Center for Information Technology (R01MH106056)
U.S. Department of Health & Human Services | National Institutes of Health (R01AG065168)
- License Information
-
More Information
Article History
Received: 26 January 2025
Revised: 3 March 2026
Accepted: 24 March 2026
First Online: 13 April 2026
Competing interests
: The authors declare no competing interests.
: All methods were performed in accordance with the relevant guidelines and regulations. All human induced pluripotent stem cell work was conducted under the oversight of the Institutional Review Board (IRB) (HS13-00500) at the Icahn School of Medicine at Mount Sinai, with informed consent from all participants. Brain tissue after death was collected at the Mount Sinai Pathology Department in accordance with the institutional policies and regulations, along with next-of-kin consent for the de-identified tissue to be used for research purposes and approved under IRB STUDY-18-00983. All animal experiments were performed in the Johns Hopkins University Brain Science Institute’s Behavioral Core according to the University’s Animal Care and Use Committee’s guidelines and approved under Protocol Number MO23M218.
